GlobeNewswire Inc | Dec 21, 2021 08:00AM EST

December 21, 2021

NEWARK, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced thatAvanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the JP Morgan Chase 40thAnnual Healthcare Conference and at theH.C. Wainwright Bioconnect Conference, both conferences being held virtually January 10-13, 2022.

Additional details can be found below:

Conference:JP Morgan Chase 40th Annual Healthcare ConferenceDate and Time:Thursday, January 13, 2022 at 11:15 a.m. ETLocation:Webcast Link-or at the companys website (click here)

Conference:H.C. Wainwright Bioconnect ConferenceDate and Time:Prerecorded presentation will be available beginning Monday, January 10, 2022 at 7:00 a.m. ETLocation:Webcast Link-or at the companys website (click here)

Replay of the corporate overview presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors underlying genetics rather than histology. Rains lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media ContactJordyn TemperatoLifeSci Communicationsjtemperato@lifescicomms.com

Investor ContactBob YedidLifeSci Advisors+1.646.597.6989bob@lifesciadvisors.com